Pharmaceutical Technology

JUNE 20, 2023

Santhera will also receive $26m for making payments of contractually agreed third-party regulatory milestone obligations, and $105m in potential sales milestones. The company will receive an additional $10m upon approval from the US FDA for vamorolone for DMD treatment.

Licensing 246

Licensing Licensing Medicine Drugs 246

Bio Pharma Dive

MAY 15, 2023

The Dutch biotech sold a portion of royalties owed by CSL Behring on sales of Hemgenix, adding to a cash pile it has built since out-licensing the treatment.

Gene Therapy 300

Gene Therapy Gene Licensing Licensing 300

Pharmaceutical Technology

OCTOBER 30, 2023

Helinus will receive €42m upfront and will be in line to receive up to €143m in regulatory and sales-based milestone payments.

Licensing 147

Licensing Licensing Antibody Marketing 147

Pharmaceutical Technology

APRIL 25, 2023

German biotechnology firm 3B Pharmaceuticals (3BP) has entered into a licensing agreement with Novartis Innovative Therapies for its fibroblast activation protein (FAP)-targeting peptide technology. Tiered royalties on net sales are also included in the deal. FAP-2286 is being investigated as a peptide-targeted radionuclide therapy.

Licensing 130

Licensing Licensing Clinical Development Clinical Trials 130

Pharmaceutical Technology

JUNE 19, 2023

Bio-Thera Solutions and Biomm have entered a licensing and supply agreement for Bio-Thera’s BAT2206, a ustekinumab biosimilar. The company stated that the collaboration will use the local presence, sales and marketing capabilities of Biomm in Brazil.

Licensing 130

Licensing Licensing Clinical Trials Clinical Trials 130

Pharmaceutical Technology

JANUARY 23, 2023

As per the terms of the agreement, HUTCHMED will receive an upfront payment of $400m on the closing of the deal, along with additional potential payments of up to $730m in regulatory, development and commercial sales milestones and royalties on net sales. The submission is planned to be completed in the first half of this year.

Licensing 130

Licensing Licensing Sales Branding 130

Pharmaceutical Technology

OCTOBER 4, 2022

Shionogi will waive royalty payments on product sales in all countries under this deal as long as Covid-19 is listed by the World Health Organization as a Public Health Emergency of International Concern. The post Shionogi and MPP enter Covid-19 antiviral licensing deal appeared first on Pharmaceutical Technology.

Licensing 147

Licensing Licensing Manufacturing Medicine 147

Pharmaceutical Technology

MARCH 21, 2023

Gilead Sciences has exercised its option to exclusively license the investigational targeted protein degrader development candidate, NX‑0479, from clinical-stage biopharmaceutical company Nurix Therapeutics. Additionally, Nurix will receive up to low double-digit tiered royalties on the net sales of the product.

Protein 130

Protein Licensing Licensing Sales 130

Fierce Pharma

FEBRUARY 29, 2024

exclusivity period on its immunology blockbuster Stelara ticks away, another biosimilar player has lined up for the piece of the drug's sales pie. | exclusivity period on Stelara ticks away, another biosimilar player has lined up for the piece of the blockbuster's sales pie. As Johnson & Johnson's U.S.

Licensing 116

Licensing Licensing Sales Drugs 116

BioTech 365

APRIL 14, 2021

Heritage Cannabis Holdings Subsidiary CannaCure Receives Amended Sales License Allowing for the Sale of Dried Cannabis Products Heritage Cannabis Holdings Subsidiary CannaCure Receives Amended Sales License Allowing for the Sale of Dried Cannabis Products TORONTO–(BUSINESS WIRE)–Heritage Cannabis Holdings Corp.

Sales 52

Sales Licensing Licensing Production 52

BioTech 365

FEBRUARY 22, 2021

Pure Extracts Submits Application to Health Canada for Sales License Pure Extracts Submits Application to Health Canada for Sales License VANCOUVER, British Columbia, Feb. 23, 2021 (GLOBE NEWSWIRE) — Pure Extracts Technologies Corp. CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure … Continue reading →

Licensing 40

Licensing Licensing Sales 40

BioPharma Reporter

MAY 6, 2021

The next step will be to start a rolling submission for a Biologics License Application (BLA) for its COVID-19 vaccine with the FDA this month. Moderna has reported the first profitable quarter in the companyâs history: after 10 years of research and several billion dollars of investment in its mRNA platform.

Licensing 97

Licensing Licensing Vaccination Vaccine 97

BioTech 365

MARCH 16, 2021

Optimi Health Receives Health Canada NPN Product Licenses in Preparation for Q2 Sales Launch Optimi Health Receives Health Canada NPN Product Licenses in Preparation for Q2 Sales Launch –Company Introduces Celebrity Wellness Expert Harley Pasternak as Advisor VANCOUVER, British Columbia, … Continue reading →

Licensing 40

Licensing Licensing Sales Production 40

Drug Discovery World

MAY 8, 2023

UK company Tay Therapeutics has entered into an exclusive license agreement with US biotech VYNE Therapeutics for its oral bromodomain and extra-terminal domain (BET) inhibitor TAY-B2. Tay Therapeutics out-licensed its topical pan-BET inhibitor to VYNE for £16m in upfront and milestone payments in 2021.

Licensing 52

Licensing Licensing Sales Development 52

pharmaphorum

FEBRUARY 28, 2024

Viatris licenses two late-stage drugs from Idorsia for heart attack and lupus, both claimed to have blockbuster sales potential, for $350m upfront.

Licensing 115

Licensing Licensing Sales Drugs 115

BioTech 365

AUGUST 10, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Pragmatism prevails for Dicerna as it looks to out-license the sales work for mixed bag nedosiran.Pragmatism prevails for Dicerna as it looks to out-license the sales work … Continue reading →

Licensing 40

Licensing Licensing Sales Research 40

BioPharma Reporter

SEPTEMBER 6, 2022

Emergence Therapeutics has become the tenth company to license ADC technology from Synaffix. The deal has a total potential value of up to US$360m, plus royalties on commercial sales.

Licensing 52

Licensing Licensing Sales Regulation 52

Bio Pharma Dive

APRIL 13, 2022

Antares Pharma's auto-injector technology is of particular interest to Halozyme, which believes that the various markets to which it could be applied represent billions of dollars in potential sales.

Drug Delivery 141

Drug Delivery Licensing Licensing Sales 141

Fierce Pharma

JANUARY 11, 2024

With sales declining for aging MS drug Fampyra, Biogen has exercised an option to return licensing rights outside of the U.S. to Acorda Therapeutics.

Licensing 118

Licensing Licensing Drugs Sales 118

AuroBlog - Aurous Healthcare Clinical Trials blog

MARCH 23, 2023

With the chemists and druggists across the country opposing the sale of drugs through online, the Central government is taking a stand that the sale of medicines should be strictly under the provisions of the existing regulations and the State Licensing Authorities (SLAs) are legally empowered to act against violation of the legal provisions.

Pharmacy 142

Pharmacy Sales Licensing Licensing 142

AuroBlog - Aurous Healthcare Clinical Trials blog

JULY 16, 2023

At least seven more pharma companies and a federation of pharma manufacturers have approached the Delhi High Court against the Central Government’s order in the beginning of June prohibiting manufacturing, distribution and sale of 14 fixed dose combinations (FDCs) licensed prior to the year 1988.

Pharma Companies 140

Pharma Companies Licensing Licensing Manufacturing 140

Pharmaceutical Technology

MAY 31, 2023

Stealth BioTherapeutics has made an exclusive licensing agreement with Pharmanovia for the commercialisation of its elamipretide to treat Barth syndrome.

Licensing 245

Licensing Licensing Sales Development 245

AuroBlog - Aurous Healthcare Clinical Trials blog

JULY 11, 2023

The Delhi High Court has granted ten days’ time to the Government of India and the nation’s drug regulator to file a counter affidavit on the petitions filed by almost 28 pharma companies against the order prohibiting manufacturing, distribution and sale of 14 FDCs licensed prior to the year 1988, in the beginning of June. […]

Pharma Companies 133

Pharma Companies Licensing Licensing Sales 133

pharmaphorum

NOVEMBER 15, 2022

Lantheus’ pipeline-building drive in radiopharma has continued with a $260 million upfront deal to license rights to two oncology candidates from POINT Biopharma. billion in milestone payments to POINT if the two radiotherapeutics get FDA approval and meet commercial objectives, plus royalties on net sales.

Licensing 52

Licensing Licensing FDA Approval Trials 52

pharmaphorum

JUNE 23, 2021

GlaxoSmithKline’s pitch to shareholders kicked off this afternoon with an optimistic view of its late-stage pipeline – including some big sales predictions for products like its respiratory syncytial virus (RSV) vaccine and new blood cancer drug Blenrep. billion takeover of Tesaro in 2019. £1 mRNA ambitions. mRNA ambitions.

Sales 100

Sales Vaccination Vaccine Drugs 100

Pharmaceutical Technology

MAY 1, 2023

The NDA is supported by the data package licensed to Ocumension by Nicox as well as the Phase III clinical trial in China. Nicox granted exclusive license to Ocumension to develop and commercialise Zerviate in China and most of the Southeast Asian markets.

Licensing 162

Licensing Licensing Sales Packaging 162

pharmaphorum

JULY 8, 2022

Swedish rare disease specialist Sobi is paying $55 million upfront to license rights to ADC Therapeutics’ lymphoma therapy Zynlonta – approved in the US last year – in Europe and other international markets. The post Sobi bolsters blood division via $435m ADC licensing deal appeared first on.

Licensing 52

Licensing Licensing Sales Marketing 52

pharmaphorum

AUGUST 18, 2021

Akili already has the first and only FDA cleared video game-based digital therapeutic (DTx) for children with attention-deficit hyperactivity disorder (ADHD), but is looking to add to its range via a licensing deal with Australia’s TALi Digital. . TALi is also in line for royalties on sales.

Licensing 64

Licensing Licensing Sales FDA Approval 64

pharmaphorum

FEBRUARY 11, 2022

The post Ipsen plans sale of consumer health business for €350m appeared first on. Ipsen’s consumer health range includes brands like diarrhoea remedy Smecta, Forlax for constipation and Ginkgo biloba supplement Tanakan, which recorded revenues of €226 million in 2021, up 8%.

Sales 103

Sales Pharma Companies Cosmetics Branding 103

Pharmaceutical Technology

MAY 12, 2023

BlissBio has the potential to earn up to $2bn in commercial milestone payments, as well as royalties on sales if Eisai exercises its option to license the drug. The drug became a blockbuster last year, with sales reaching $1.9bn, up from $599m in 2021. targeting ADC.

Clinical Trials 162

Clinical Trials Clinical Trials Licensing Licensing 162

Drug Discovery World

APRIL 17, 2024

Biotechnology company Arvinas has entered into an exclusive strategic license agreement with Novartis for ARV-766, Arvinas’ second generation PROTAC androgen receptor (AR) degrader for patients with prostate cancer. Arvinas will receive an upfront payment in the aggregate amount of $150 million.

Protein 52

Protein Licensing Licensing Sales 52

The Pharma Data

NOVEMBER 9, 2021

Group sales rise by 14.3 percent to 2.089 billion euros / Crop Science reports strong increase in sales and earnings / Pharmaceuticals and Consumer Health again post considerable sales growth / Core earnings per share advance by 29.6 percent (Fx & portfolio adj.) percent to 1.05

Sales 52

Sales Licensing Licensing Production 52

The Pharma Data

MAY 13, 2021

Product Name: Total Dental Health ebook sales page | Health Guru Mike. Click here to get Total Dental Health ebook sales page | Health Guru Mike at discounted price while it’s still available… All orders are protected by SSL encryption – the highest industry standard for online security from trusted vendors.

Sales 52

Sales Production Licensing Licensing 52

The Pharma Data

JANUARY 12, 2021

13, 2021 /PRNewswire/ — EVOQ Therapeutics today announced a license and collaboration agreement with Amgen for the discovery and development of novel drugs for autoimmune disorders. EVOQ Therapeutics today announced a license and collaboration agreement with Amgen. ANN ARBOR, Mich. ,

Licensing 52

Licensing Licensing Clinical Development Sales 52

The Pharma Data

AUGUST 5, 2020

AstraZeneca has signed a licensing deal with UK-based biotech company Redx Pharma for its fibrotic disease candidate RXC006. Redx is also eligible to receive up to $360m in additional payments, dependent on development, regulatory and commercial milestones, as well as tiered royalties on any future sales.

Licensing 52

Licensing Licensing Clinical Trials Clinical Trials 52

pharmaphorum

NOVEMBER 10, 2021

The drug was the first in the oral CGRP inhibitor class to get an prevention indication approved by the FDA in May, and that has helped accelerate its rollout, bringing in $336 million in US sales for Biohaven so far this year. The post Pfizer strikes $1.2bn licensing deal for Biohaven migraine drug appeared first on.

Licensing 52

Licensing Licensing Drugs Sales 52

pharmaphorum

AUGUST 10, 2021

Seagen announced an exclusive license for a late-stage, novel and potentially differentiated ADC, complementing our diverse oncology pipeline and portfolio of marketed products and global footprint. While the licensing deal with Seagen tops up its finances, the scale well below the $6.9 Sales last year grew by a third to $1.7

Licensing 52

Licensing Licensing Antibody Sales 52